<SEC-DOCUMENT>0001125345-21-000103.txt : 20210908
<SEC-HEADER>0001125345-21-000103.hdr.sgml : 20210908
<ACCEPTANCE-DATETIME>20210908161048
ACCESSION NUMBER:		0001125345-21-000103
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210907
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210908
DATE AS OF CHANGE:		20210908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		211242259

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mgnx-20210907.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:e9f28fee-675f-4371-931a-d4dd119ed219,g:34c68fe2-b228-4e06-8e4d-da10c015a835,d:c14a850837304dcb99973bcf96210eb5--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20210907</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV80L2ZyYWc6NjE3NGQ3MTFmYmI2NDE4Mjk3OTY3OWFhNmM2ZDZjMjcvdGFibGU6NTJmMzlmYmFhNWY4NGRjNWFmYjU1OWQyMTZjNDRmMzEvdGFibGVyYW5nZTo1MmYzOWZiYWE1Zjg0ZGM1YWZiNTU5ZDIxNmM0NGYzMV8yLTEtMS0xLTk1MTM_06b009e3-e51e-4fea-9199-1defe40f228f">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV80L2ZyYWc6NjE3NGQ3MTFmYmI2NDE4Mjk3OTY3OWFhNmM2ZDZjMjcvdGFibGU6NTJmMzlmYmFhNWY4NGRjNWFmYjU1OWQyMTZjNDRmMzEvdGFibGVyYW5nZTo1MmYzOWZiYWE1Zjg0ZGM1YWZiNTU5ZDIxNmM0NGYzMV8zLTEtMS0xLTk1MTM_7d0f16b0-bbd7-4f91-988c-7ce857f89843">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20210907.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-07</xbrli:startDate><xbrli:endDate>2021-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic14a850837304dcb99973bcf96210eb5_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQx_be8c1b03-761a-4644-9b97-b0396e9b52ca">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18yMzI_e1b389a1-d1ef-4ed7-9d7a-9d10e5a6601c">September 7, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQy_3d28fe8f-ad5d-4269-9693-3cf93ff68252">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (Exact Name of Registrant as Specified in Charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.948%"><tr><td style="width:1.0%"></td><td style="width:18.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.968%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTAtMS0xLTk1MTM_f053355b-a91d-49f6-893f-12733a861773">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTMtMS0xLTk1MTM_455284e9-2f8a-4be2-b06f-ae59cb98b5e2">001-36112</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTUtMS0xLTk1MTM_10fa0c12-e66c-4289-973b-df6c60892054">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8zLTAtMS0xLTk1MTM_47f35430-4a7a-4ba5-980a-b958b6b91a32">9704 Medical Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTAtMS0xLTk1MTM_84d7cac3-87d9-47a1-99fb-6bccdb91c7f6">Rockville,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTEtMS0xLTk1MTM_f2224a91-4925-43e0-bd62-811e7c194ea3">Maryland</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTMtMS0xLTk1MTM_ced81158-77f9-400d-9a23-9d1ea4cbe8c8">20850</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQz_f88e5062-04be-4341-b8c3-527cccf55de4">301</ix:nonNumeric>) <ix:nonNumeric contextRef="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ0_3b02ef2f-e3b1-4058-93e4-9d34d25c71bc">251-5172</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTAtMS0xLTk1MTM_b4d86d45-3db3-498c-b6fe-cd8c730aa0b1">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTEtMS0xLTk1MTM_ad197fcd-e43f-4691-8834-0f24b7a5e748">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTItMS0xLTk1MTM_3e909733-c848-434d-b54f-4418946a7056">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:5.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ1_2d9d7c9b-f0f9-42e2-a33e-e91751387e7b">&#9744;</ix:nonNumeric> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ2_4da793ea-c605-4517-a91b-053ac2009f7a">&#9744;</ix:nonNumeric> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ3_5b854e5b-c50c-4fc7-8de5-c08a6779e630">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ4_db95b902-9113-4f85-b8ce-725bd4401b06">&#9744;</ix:nonNumeric> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQw_6276fc0a-16c1-4b16-b823-9fe7fbd29404">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   &#9744;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic14a850837304dcb99973bcf96210eb5_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 8.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Other Events.</span></div></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 7, 2021, MacroGenics, Inc. issued a press release announcing final overall survival (OS) results of the SOPHIA Phase 3 Study in adult patients with HER2-positive metastatic breast cancer.  The SOPHIA study is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. In 2020, MARGENZA was approved by the U.S. Food and Drug Administration (FDA) in combination with chemotherapy for the treatment of adult patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The basis for the FDA approval was the previously disclosed progression-free survival (PFS) results in the SOPHIA study. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A copy of the press release (the &#8220;Press Release") is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. </span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:14.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibits.</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:21.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="sophiapressrelease9721.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="sophiapressrelease9721.htm">Press Release dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="sophiapressrelease9721.htm">September </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="sophiapressrelease9721.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline" href="sophiapressrelease9721.htm">, 2021</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data (embedded within the Inline XBRL document)</span></td></tr></table></div><div><span><br/></span></div><div id="ic14a850837304dcb99973bcf96210eb5_10"></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:  September 8, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></div><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name:</span></div><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Peters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vice President and General Counsel</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sophiapressrelease9721.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iaa7ce7db54a94d0eb56cbcfc492f9e87_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA&#8482; in Patients with HER2-Positive Metastatic Breast Cancer    </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumab</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">OS was greater with MARGENZA plus chemotherapy in exploratory subgroups of patients carrying a CD16A 158F allele compared to trastuzumab plus chemotherapy arm, while the OS for trastuzumab plus chemotherapy was greater than MARGENZA plus chemotherapy for the small exploratory subgroup of patients homozygous for the CD16A 158V allele</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">The safety profile remains similar to what has been reported previously</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROCKVILLE, MD, Sept. 7, 2021 (GLOBE NEWSWIRE) &#8211; MacroGenics, Inc. (NASDAQ&#58; MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:line-through"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2020, MARGENZA (margetuximab-cmkb) was approved by the U.S. Food and Drug Administration (FDA) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. The basis for this full approval was the progression-free survival (PFS) results in the SOPHIA study, which compared MARGENZA plus chemotherapy to trastuzumab plus chemotherapy in patients with metastatic HER2-positive breast cancer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The final OS analysis of the SOPHIA study was performed after 385 OS events occurred in the intent-to-treat (ITT) population. As per the study protocol, OS was defined as the number of days from randomization to the date of death (from any cause). The final OS analysis for the ITT population did not demonstrate a statistically significant advantage for MARGENZA plus chemotherapy </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">compared to that of patients who received trastuzumab plus chemotherapy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (hazard ratio &#91;HR&#93;&#61;0.95&#59; 95% Confidence Interval &#91;CI&#93;&#58; 0.77-1.17&#59; P&#61;0.62). In this overall ITT population, the median survival was 21.6 months in patients treated with MARGENZA plus chemotherapy (N&#61;266) compared to 21.9 months in patients treated with trastuzumab plus chemotherapy (N&#61;270).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A pre-specified, non-alpha-allocated exploratory analysis evaluated the effect of CD16A allelic variation on MARGENZA activity. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Among the patients in the trial carrying a CD16A 158F allele, representing approximately 82% of</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> study </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">patients (437 of 536 patients), the median OS was prolonged by 2.5 months in the MARGENZA arm compared to the trastuzumab arm (23.3 months versus 20.8 months&#59; HR&#61;0.86&#59; 95% CI&#58; 0.69-1.08&#59; nominal P&#61;0.19). </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The numerical OS advantage was observed in the subgroup of CD16A patients who were homozygous for the F-allele at position 158 (i.e., &#8220;F&#47;F&#8221; patients) in favor of MARGENZA plus chemotherapy (HR&#61;0.72&#59; 95% CI&#58; 0.52-1.00&#59; nominal P&#61;0.05). In this subgroup, the median OS was 23.6 months in patients treated with MARGENZA plus chemotherapy (102 of 266 patients) compared to 19.2 months in patients treated with trastuzumab plus chemotherapy (90 of 270 patients).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the subgroup of CD16A F&#47;V patients, the median OS was 21.3 months in patients treated with MARGENZA plus chemotherapy (119 of 266 patients)</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">compared to 22.0 months in patients treated with trastuzumab plus chemotherapy (126 of 270 patients) (</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">HR&#61;0.96&#59; 95% CI&#58; 0.71-1.30&#59; nominal P&#61;0.78)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">In a small subgroup of CD16A V&#47;V patients, OS was greater for trastuzumab plus chemotherapy than MARGENZA plus chemotherapy (HR&#61;1.77&#59; 95% CI&#58; 1.01-3.12&#59; nominal P&#61;0.04). In this subgroup, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">median survival was 22.0 months in patients treated with MARGENZA plus chemotherapy (37 of 266 patients) compared to 31.1 months in patients treated with trastuzumab plus chemotherapy (32 of 270 patients).</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The safety profile at the time of the final OS analysis of SOPHIA was similar to what was previously reported and consistent with the product&#8217;s existing FDA-approved label. Adverse reactions occurring in greater than 20% of patients with MARGENZA in combination with chemotherapy were consistent with the existing product label. The MARGENZA U.S. Prescribing Information has a BOXED WARNING for left ventricular dysfunction and embryo-fetal toxicity. In addition, MARGENZA can cause infusion related reactions (IRRs). As stated in the U.S. Prescribing Information, IRRs occurred in 13% of patients treated with MARGENZA, with the majority reported as Grade 2 or less. Grade 3 IRRs occurred in 1.5% of patients. See below for Important Safety Information.</font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#8220;While the OS results in the SOPHIA ITT population are disappointing, the greater OS observed in the CD16A subgroup of patients with the lowest binding allelic variant of CD16 to the Fc region of IgG1 &#8212; namely, the F&#47;F allele representing about 40% of all individuals (35.8% in this study) &#8212; is consistent with enhancements observed in MARGENZA&#8217;s engineered Fc region,&#8221; said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. &#8220;Therefore, further studies are warranted to determine the impact of MARGENZA on HER2-positive breast cancer patients with different CD16A allelic variants, including the ongoing investigator-sponsored neoadjuvant study examining the effects of MARGENZA versus trastuzumab in patients expressing F-allelic variants of CD16A. We continue to believe MARGENZA may be the right choice for certain patients,&#8221; added Dr. Koenig. </font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">The data will be submitted to the FDA and presented at a future scientific meeting. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WARNING&#58; LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Left Ventricular Dysfunction&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> MARGENZA may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate cardiac function prior to and during treatment. Discontinue MARGENZA treatment for a confirmed clinically significant decrease in left ventricular function.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Embryo-Fetal Toxicity&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exposure to MARGENZA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WARNINGS &#38; PRECAUTIONS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Left Ventricular Dysfunction</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Left ventricular cardiac dysfunction can occur with MARGENZA.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In SOPHIA, left ventricular dysfunction occurred in 1.9% of patients treated with MARGENZA.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MARGENZA has not been studied in patients with a pretreatment LVEF value of &#60;50%, a prior history of myocardial infarction or unstable angina within 6 months, or congestive heart failure NYHA class II-IV.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Withhold MARGENZA for &#8805;16% absolute decrease in LVEF from pretreatment values or LVEF below institutional limits of normal (or 50% if no limits available) and &#8805;10% absolute decrease in LVEF from pretreatment values.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Permanently discontinue MARGENZA if LVEF decline persists greater than 8 weeks, or dosing is interrupted more than 3 times due to LVEF decline.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Evaluate cardiac function within 4 weeks prior to and every 3 months during and upon completion of treatment. Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Monitor cardiac function every 4 weeks if MARGENZA is withheld for significant left ventricular cardiac dysfunction.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Embryo-Fetal Toxicity</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Based on findings in animals and mechanism of action, MARGENZA can cause fetal harm when administered to a pregnant woman. Post-marketing studies of other HER2 directed antibodies during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Verify pregnancy status of women of reproductive potential prior to initiation of MARGENZA.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advise pregnant women and women of reproductive potential that exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Advise women of reproductive potential to use effective contraception during treatment and for 4 months following the last dose of MARGENZA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Infusion-Related Reactions (IRRs)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">MARGENZA can cause IRRs. Symptoms may include fever, chills, arthralgia, cough, dizziness, fatigue, nausea, vomiting, headache, diaphoresis, tachycardia, hypotension, pruritus, rash, urticaria, and dyspnea.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In SOPHIA, IRRs were reported by 13% of patients on MARGENZA plus chemotherapy. Most of the IRRs occur during Cycle 1. Grade 3 IRRs were reported in 1.5% of MARGENZA-treated patients.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Monitor patients during and after MARGENZA infusion. Have medications and emergency equipment to treat IRRs available for immediate use.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">In patients experiencing mild or moderate IRRs, decrease rate of infusion and consider premedications, including antihistamines, corticosteroids, and antipyretics. Monitor patients until symptoms completely resolve.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with supportive medical therapy as needed. Permanently discontinue MARGENZA in all patients with severe or life-threatening IRRs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MOST COMMON ADVERSE REACTIONS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The most common adverse drug reactions (&#62;10%) with MARGENZA in combination with chemotherapy are fatigue&#47;asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia&#47;myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov&#47;medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDICATION</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA is a HER2&#47;neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Please see full Prescribing Information, including Boxed Warning.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About the SOPHIA Study</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The SOPHIA study (NCT02492711) is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, who have previously been treated with anti-HER2-targeted therapies. All study patients had previously received trastuzumab, all but one patient had previously received pertuzumab, and 91% had previously received ado-trastuzumab emtansine, or T-DM1.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The study enrolled 536 patients who were randomized 1&#58;1 to receive either MARGENZA (n&#61;266) given intravenously at 15 mg&#47;kg every three weeks or trastuzumab (n&#61;270) given intravenously at 6 mg&#47;kg (or 8 mg&#47;kg for loading dose) every three weeks in combination with one of four chemotherapy agents (capecitabine, eribulin, gemcitabine or vinorelbine) given at the standard dose. Intent-to-treat PFS analysis occurred after 265 PFS events.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The primary endpoints of the study were sequentially-assessed PFS, determined by blinded, centrally-reviewed radiological review, followed by OS. Additional key secondary endpoints are PFS by investigator assessment and ORR. Tertiary endpoints include ORR by investigator assessment and safety. PFS and ORR were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About HER2-positive Breast Cancer</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Human epidermal growth factor receptor 2 (HER2) is a protein found on the surface of some cancer cells that promotes growth and is associated with aggressive disease and poor prognosis. Approximately 15-20% of breast cancer cases are HER2-positive. Monoclonal antibodies targeting HER2 have greatly improved outcomes&#59; however, a significant number of patients progress to later lines of therapy. Effective treatments for metastatic HER2-positive breast cancer continue to remain an unmet need.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MARGENZA</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA (margetuximab-cmkb) is an Fc-engineered, monoclonal antibody that targets the HER2 oncoprotein. HER2 is expressed by tumor cells in breast, gastroesophageal and other solid tumors. Similar to trastuzumab, margetuximab-cmkb inhibits tumor cell proliferation, reduces shedding of the HER2 extracellular domain and mediates antibody-dependent cellular cytotoxicity (ADCC). However, through MacroGenics&#8217; Fc Optimization technology, margetuximab-cmkb has been engineered to enhance the engagement of the immune system. In vitro, the modified Fc region of margetuximab-cmkb increases binding to the activating Fc receptor FCGR3A (CD16A) and decreases binding to inhibitor Fc receptor FCGR2B (CD32B).&#160; These changes lead to greater in vitro ADCC and NK cell activation.&#160; The clinical significance of in vitro data is unknown. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MARGENZA is also being evaluated in combination with checkpoint blockade in the Phase 2&#47;3 MAHOGANY trial for the treatment of patients with HER2-positive gastroesophageal cancer (NCT04082364), and in combination with tebotelimab (PD-1 &#215; LAG-3 bispecific DART&#174; molecule) in various HER2+ tumors (NCT03219268). In addition, MARGENZA is being evaluated in an investigator-sponsored, Phase 2 neoadjuvant study in patients with stage 2-3 HER2-positive breast cancer (NCT04425018). For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MacroGenics, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.macrogenics.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. MacroGenics, the MacroGenics logo and MARGENZA are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Note on Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, commercial prospects of or product revenues from MARGENZA, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and other statements containing the words &#34;subject to&#34;, &#34;believe&#34;, &#34;anticipate&#34;, &#34;plan&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;estimate&#34;, &#34;project&#34;, &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;would&#34;, &#34;could&#34;, &#34;can&#34;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including&#58; risks that MARGENZA revenue, expenses and costs may not be as expected, risks relating to MARGENZA&#8217;s market acceptance, competition, reimbursement and regulatory actions, the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACTS&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chris James, M.D., Vice President, Investor Relations &#38; Corporate Communications</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jim Karrels, Senior Vice President, CFO</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-301-251-5172, </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">info&#64;macrogenics.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>mgnx-20210907.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9f28fee-675f-4371-931a-d4dd119ed219,g:34c68fe2-b228-4e06-8e4d-da10c015a835-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20210907" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20210907">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210907_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20210907_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://macrogenics.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>mgnx-20210907_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9f28fee-675f-4371-931a-d4dd119ed219,g:34c68fe2-b228-4e06-8e4d-da10c015a835-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_6c33f694-20fd-466e-b62f-51a90a52e8f4_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_899ea2ef-91cd-468c-8d38-691092807b20_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a2f66689-c448-4d74-9575-5a96da736bad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_82f64746-070c-4ef9-8c15-3a9ecd8e3e00_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6dd6bd33-1634-4905-be35-8bea3d38b289_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6bed2085-5f3d-4642-8be1-9cd9f1b01d0e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_a431a115-5fad-4638-8755-309944bfe1e0_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_77d9376c-7caa-42b7-957f-276907c55ded_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e523281-7303-43c9-b0c6-810c60a22582_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fdffc7de-41bf-4fc9-971b-4f0bcc771510_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a03e7d5c-ce8b-402b-b1c1-efb3cec1c1ea_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_506ac96b-7cab-45a5-86cf-8642c8dd2e63_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_84c126c7-28dd-406e-a0f3-bb55db9637a8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_61d6da9d-df6d-41e5-aa99-1ccf8fb51dc2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_cda4550f-5afa-436d-9502-628f7eb55ba0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_34861ed3-d243-4598-a9da-c98b8c88d352_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_02642ce0-2104-42aa-8136-d37b720839a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_35d4a235-094f-4750-8b8c-8d0eaf3ac953_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_21689d01-ac1a-4e76-a4c5-e5c35552c46c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7d901116-7c1e-416c-a44e-70e8fbf6a27d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2c59d949-6916-4a78-9725-ed7d59044b65_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f3c7cef9-563a-4d34-b8b0-93875a7f150b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8ebd23ef-929f-4a6f-bf2d-df49f51765b7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>mgnx-20210907_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:e9f28fee-675f-4371-931a-d4dd119ed219,g:34c68fe2-b228-4e06-8e4d-da10c015a835-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/Cover" xlink:type="simple" xlink:href="mgnx-20210907.xsd#Cover"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_61ad3c6b-26e5-4549-8e51-ffba73d4932d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_DocumentType_61ad3c6b-26e5-4549-8e51-ffba73d4932d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_00e24966-79a5-4cb7-a320-8eb18ded6e85" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_DocumentPeriodEndDate_00e24966-79a5-4cb7-a320-8eb18ded6e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0051a6c3-65d2-4f12-bab3-6d4b13d150fe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityRegistrantName_0051a6c3-65d2-4f12-bab3-6d4b13d150fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f50bde23-706f-401e-a874-4a723b044329" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f50bde23-706f-401e-a874-4a723b044329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_702c464b-2b93-4438-8516-cb2e3b555df3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityFileNumber_702c464b-2b93-4438-8516-cb2e3b555df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c13be579-d3ae-4b39-a3b2-29999a2073c1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityTaxIdentificationNumber_c13be579-d3ae-4b39-a3b2-29999a2073c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a591f92f-eb32-4f66-a8ce-63319e5d77d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityAddressAddressLine1_a591f92f-eb32-4f66-a8ce-63319e5d77d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_60b8898e-c649-4b8c-a297-be75c5db9b11" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityAddressCityOrTown_60b8898e-c649-4b8c-a297-be75c5db9b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b1186463-bbb0-4f68-bc34-3fb0a9b91649" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityAddressStateOrProvince_b1186463-bbb0-4f68-bc34-3fb0a9b91649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_70358dd1-6719-44e0-bdce-1f158136c75a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityAddressPostalZipCode_70358dd1-6719-44e0-bdce-1f158136c75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_86957fdf-9d29-4e1b-8d50-fa164cf8c4df" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_CityAreaCode_86957fdf-9d29-4e1b-8d50-fa164cf8c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_0967e2cb-5eaf-4fe6-b6cb-80722d9621ed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_LocalPhoneNumber_0967e2cb-5eaf-4fe6-b6cb-80722d9621ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_a19ffe9d-198b-46a1-8efc-e6a3e108b6d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_Security12bTitle_a19ffe9d-198b-46a1-8efc-e6a3e108b6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2f3bbc78-ead1-4b22-a475-3657f8a11c7e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_TradingSymbol_2f3bbc78-ead1-4b22-a475-3657f8a11c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ce2c09ff-ad19-4342-a112-871caa1ffc8b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_SecurityExchangeName_ce2c09ff-ad19-4342-a112-871caa1ffc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d36e3e65-1bac-401c-8a6c-3b329f725bef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_WrittenCommunications_d36e3e65-1bac-401c-8a6c-3b329f725bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_e7312a8c-2640-4363-933f-a2aa87bca3fa" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_SolicitingMaterial_e7312a8c-2640-4363-933f-a2aa87bca3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b213550d-508a-4ddf-96cb-243c57031491" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_PreCommencementTenderOffer_b213550d-508a-4ddf-96cb-243c57031491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ca93b0b4-5295-4d54-98b4-2ef4d42c4778" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ca93b0b4-5295-4d54-98b4-2ef4d42c4778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2dc76ed8-0d8b-48c3-89a0-5b36f1372bd8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityEmergingGrowthCompany_2dc76ed8-0d8b-48c3-89a0-5b36f1372bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_28827d70-ebc0-4f45-8f65-60db41fcd73e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_EntityCentralIndexKey_28827d70-ebc0-4f45-8f65-60db41fcd73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a4daeb51-e5a4-4890-be19-7ec71312aa32" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_AmendmentFlag_a4daeb51-e5a4-4890-be19-7ec71312aa32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e956fc7a-9058-447a-b16f-f9e460fdd4fc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f1b4304-226e-4512-8a97-89e318d6baa8" xlink:to="loc_dei_CurrentFiscalYearEndDate_e956fc7a-9058-447a-b16f-f9e460fdd4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>mgnx-20210907_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20210907.xsd" xlink:type="simple"/>
    <context id="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-09-07</startDate>
            <endDate>2021-09-07</endDate>
        </period>
    </context>
    <context id="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV80L2ZyYWc6NjE3NGQ3MTFmYmI2NDE4Mjk3OTY3OWFhNmM2ZDZjMjcvdGFibGU6NTJmMzlmYmFhNWY4NGRjNWFmYjU1OWQyMTZjNDRmMzEvdGFibGVyYW5nZTo1MmYzOWZiYWE1Zjg0ZGM1YWZiNTU5ZDIxNmM0NGYzMV8yLTEtMS0xLTk1MTM_06b009e3-e51e-4fea-9199-1defe40f228f">0001125345</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV80L2ZyYWc6NjE3NGQ3MTFmYmI2NDE4Mjk3OTY3OWFhNmM2ZDZjMjcvdGFibGU6NTJmMzlmYmFhNWY4NGRjNWFmYjU1OWQyMTZjNDRmMzEvdGFibGVyYW5nZTo1MmYzOWZiYWE1Zjg0ZGM1YWZiNTU5ZDIxNmM0NGYzMV8zLTEtMS0xLTk1MTM_7d0f16b0-bbd7-4f91-988c-7ce857f89843">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQx_be8c1b03-761a-4644-9b97-b0396e9b52ca">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18yMzI_e1b389a1-d1ef-4ed7-9d7a-9d10e5a6601c">2021-09-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQy_3d28fe8f-ad5d-4269-9693-3cf93ff68252">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTAtMS0xLTk1MTM_f053355b-a91d-49f6-893f-12733a861773">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTMtMS0xLTk1MTM_455284e9-2f8a-4be2-b06f-ae59cb98b5e2">001-36112</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8wLTUtMS0xLTk1MTM_10fa0c12-e66c-4289-973b-df6c60892054">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl8zLTAtMS0xLTk1MTM_47f35430-4a7a-4ba5-980a-b958b6b91a32">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTAtMS0xLTk1MTM_84d7cac3-87d9-47a1-99fb-6bccdb91c7f6">Rockville,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTEtMS0xLTk1MTM_f2224a91-4925-43e0-bd62-811e7c194ea3">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6ZjQzZDZhM2RhNGEzNGNjN2JlMmE0NGY0ZTVlMDNkMDYvdGFibGVyYW5nZTpmNDNkNmEzZGE0YTM0Y2M3YmUyYTQ0ZjRlNWUwM2QwNl80LTMtMS0xLTk1MTM_ced81158-77f9-400d-9a23-9d1ea4cbe8c8">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQz_f88e5062-04be-4341-b8c3-527cccf55de4">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0f12c1db3c5848368357336cfbaed02d_D20210513-20210513"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ0_3b02ef2f-e3b1-4058-93e4-9d34d25c71bc">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTAtMS0xLTk1MTM_b4d86d45-3db3-498c-b6fe-cd8c730aa0b1">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTEtMS0xLTk1MTM_ad197fcd-e43f-4691-8834-0f24b7a5e748">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGFibGU6OGU0MTY4M2IzNWNkNDA2NWFlNGJlMDQ1ZmVlMDFhNjYvdGFibGVyYW5nZTo4ZTQxNjgzYjM1Y2Q0MDY1YWU0YmUwNDVmZWUwMWE2Nl8xLTItMS0xLTk1MTM_3e909733-c848-434d-b54f-4418946a7056">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ1_2d9d7c9b-f0f9-42e2-a33e-e91751387e7b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ2_4da793ea-c605-4517-a91b-053ac2009f7a">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ3_5b854e5b-c50c-4fc7-8de5-c08a6779e630">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQ4_db95b902-9113-4f85-b8ce-725bd4401b06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxNGE4NTA4MzczMDRkY2I5OTk3M2JjZjk2MjEwZWI1L3NlYzpjMTRhODUwODM3MzA0ZGNiOTk5NzNiY2Y5NjIxMGViNV8xL2ZyYWc6YTRhMWI1YWJhMzIyNDdhZjk3ZGY1MzgxY2VlODQ3MTcvdGV4dHJlZ2lvbjphNGExYjVhYmEzMjI0N2FmOTdkZjUzODFjZWU4NDcxN18xNjQw_6276fc0a-16c1-4b16-b823-9fe7fbd29404">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140697724612360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
<th class="th"><div>May 13, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  07,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">251-5172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML@_ _;52YGU@MZGESQ+#?P%02P,$%     @ 5X$H4Y^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %>!*%/8[/M4200  *(0   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !7@2A3GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( %>!*%.7BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( %>!*%.JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !7@2A3)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !7@2A399!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mgnx-20210907.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mgnx-20210907.htm">mgnx-20210907.htm</File>
    <File>mgnx-20210907.xsd</File>
    <File>mgnx-20210907_lab.xml</File>
    <File>mgnx-20210907_pre.xml</File>
    <File>sophiapressrelease9721.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20210907.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 2,
   "dts": {
    "inline": {
     "local": [
      "mgnx-20210907.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20210907_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20210907_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20210907.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20210907",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210907.htm",
      "contextRef": "ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://macrogenics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20210907.htm",
      "contextRef": "ib95b9058720142fa9b92ba1ec9759bea_D20210907-20210907",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://macrogenics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001125345-21-000103-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-21-000103-xbrl.zip
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MNNUE,#N88916@W'VN=3+LF&U4KFZNBJ/W20LQ\EY)8C"(.)BNI4LH5'JQ\F
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M?E_D9D7GG*%CX5:A0YIFJ)5GV-[/UOI);;B8KV7!E*8V!4Z*(6ME0\L]ATT
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MN'Q$['_G+4FRB^4E;2V[VVO>J%C0FWJWFBVCM[90]15$?]:+M+XOWXHTV-G
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M_=8:$F)U!2=P )(X\0'%<418E$+B)W;*?S;"1$6_1NG5,#V%TU;MSXDT%?H
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MSX@=,9L)ETC<^#WD\H <7_)8&J97)7^+NR#69;)N[1;'#@#E<Z,B,XQ;T9O
M+OP'?=<&.AJ@.>$M>@*5+AHMB0!A=MQY :!Y%$XV>F"GP)P#=^^P>X0DT^OV
M<XCO5[C=:BV )5C\<V/N=5J]$F_BPP5=Q4$UAD"H*]@4?]_K=%O=; "0-QHX
MM]-N'=M;1CJAL"/Q=-POR;EQ)LGZ)R#)VL?FIQ"4)2J^3*(Y)_OU=/UWV!Z@
MT.%EU^KA7&\B$-44QET6YD0YD&'(N:*=5@+LTYJXQGG3!FM HQD##3@;&('M
MR99H-<@][+1/SU\^/SS"O^$*G,4<O3C[C"]57([DULG/' 5'G3H4]#J(@G8]
M"MJ]DE+)]EE'6$ +/Z9 G'8'-P(:I+3%,@DZ)ZW.CZJ2DS;-<=0NYMAEG3*^
MC[X,37S,=U&+$:?@SC^'$>=D"R,[)?X>1394K)M.J_VC).ET^ELTR?9V"LZY
M #FIE>%'#@B0[CT"Y.BXEF;^ZB7_,:[.<X0\GLNP.55)HH)7?RA:_,.K[AE^
MYS90OLWS'[=X?B.K\.VX_;=B]9FJ<,##V,8T: FGV6TYG7M4Q>&]JN)>@)<3
MLID*?!4+GP*4]Z9H+7[:Q2M\JI6?)O>_4L4L++9 [KV)7?/W(BZR"W/1Q #*
M79."#*^XOP)?_]G?EF;>%3*M=2"_1Q0^1'K&@+U?_7?!X_U16=OM?+?Z_SM-
MS8U$#)B#9&[+0&3QKMI F V"(?0W<S;&U,^R-$7FQF0$0A@  V 69B:0Z:5N
M0@F)HU-P2;]@_ B\K_.S03./$/M\*OP6&WAH[&,<%KU/&,W&UTQZH9H8A#U6
MHS45,OAF#)E,Y[H%YPNT*\_6-BD[,13*O@97THWE%!\>AQ@D-)-A6HNSMU?_
M&IVQ3X.;R_'E.Y*@F"=C&#8$XS]%F'IK/4M#VBG!3P33>*V:@#) 20*NJ4O^
M-\INSY,FS)(OP0484&0/]CI+,5#,2+P!- OP[8UO;H 2,>B(H;O"L7AH PV&
M;U5"FTZW"NQ:WFL40 SX[RJ&Q9?H0[-W,?<$ZS "A=8M>Z-;,UVK5YFOQ6Z%
M8( &M2)(C@,<%<..MX; 2ZO_]]3/UB/[5,Z6U\?X-^*T(,0PO0"<I"2%-8Q>
MS%@%AMGT*8W.KTV1Y_@#0 N=,* ,CR(EY4A1F(>0,O?]W*6D" :09FP\?^>8
M_&,'-#D/A+\V2[+>9E9'4 W%3%6:L$/#TFBDX,1+Z:7<!R+N]EK'+\SRT0#
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MV&+72B=-T(IW%(?/<T$P#:6G*;\#ID,L7)-9IQ-T4NCMP)5)$1I_Q(4-F4%
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M8$)28K=HF1D63<WF\ #Z6  E^(\!'^@5I\>".6G,N[DM?4 71MCRAXV.#-F
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M?O#/(@G\-_\/4$L! A0#%     @ 5X$H4YMYK3)\%0  1HL  !$
M     ( !     &UG;G@M,C R,3 Y,#<N:'1M4$L! A0#%     @ 5X$H4^OP
M-01K @  :P<  !$              ( !JQ4  &UG;G@M,C R,3 Y,#<N>'-D
M4$L! A0#%     @ 5X$H4Y\B5Z>N"@   6$  !4              ( !11@
M &UG;G@M,C R,3 Y,#=?;&%B+GAM;%!+ 0(4 Q0    ( %>!*%,[R $@W08
M /$R   5              "  28C  !M9VYX+3(P,C$P.3 W7W!R92YX;6Q0
M2P$"% ,4    " !7@2A3='@;/I\<  "=A   &@              @ $V*@
M<V]P:&EA<')E<W-R96QE87-E.3<R,2YH=&U02P4&      4 !0!, 0  #4<
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
